Lannett to distribute generic Noxafil
Lannett has entered into an agreement with Sinotherapeutics, a China-based specialty pharmaceutical company, to be the exclusive U.S. distributor of posaconazole delayed-release tablets in a dosage strength of 100 mg.
The product is the generic of Merck's Noxafil delayed-release tablets.
Lannett expects to begin shipping the product shortly.
The brand product had a market value of approximately $325 million for the 12 months ended June 2019, according to IQVIA, although actual generic market values are expected to be lower.
"The Sinotherapeutics team is highly skilled at formulating particularly difficult to develop products, such as posaconazole delayed-release tablets," Lannett CEO Tim Crew said. "Given the market dynamics of the product, we expect posaconazole to be a meaningful contributor to our business."
Lannett will make milestone payments based on market dynamics and performance. The company will provide sales, marketing and distribution and will receive a share of the profits. Other terms were not disclosed.
The product is the generic of Merck's Noxafil delayed-release tablets.
Lannett expects to begin shipping the product shortly.
The brand product had a market value of approximately $325 million for the 12 months ended June 2019, according to IQVIA, although actual generic market values are expected to be lower.
"The Sinotherapeutics team is highly skilled at formulating particularly difficult to develop products, such as posaconazole delayed-release tablets," Lannett CEO Tim Crew said. "Given the market dynamics of the product, we expect posaconazole to be a meaningful contributor to our business."
Lannett will make milestone payments based on market dynamics and performance. The company will provide sales, marketing and distribution and will receive a share of the profits. Other terms were not disclosed.